Probiotic?derived ferrichrome inhibits the growth of refractory pancreatic cancer cells.

ABSTRACT: Pancreatic cancer is associated with a poor prognosis due to challenges in early detection, severe progression of the primary tumor, metastatic lesions, and resistance to antitumor agents. However, previous studies have indicated a relationship between the microbiome and pancreatic cancer outcomes. Our previous study demonstrated that ferrichrome derived from Lactobacillus casei, a probiotic bacteria, exhibited tumor?suppressive effects in colorectal and gastric cancer, and that the suppressive effects were stronger than conventional antitumor agents, such as 5?fluorouracil (5?FU) and cisplatin, suggesting that certain probiotics exert antitumorigenic effects. However, whether or not probiotic?derived molecules, including ferrichrome, exert a tumor?suppressive effect in other gastrointestinal tumors, such as pancreatic cancer, remains unclear. In the present study, it was demonstrated that probiotic?derived ferrichrome inhibited the growth of pancreatic cancer cells, and its tumor?suppressive effects were further revealed in 5?FU?resistant pancreatic cancer cells in vitro and in vivo in a mouse xenograft model. Ferrichrome inhibited the progression of cancer cells via dysregulation of the cell cycle by activating p53. DNA fragmentation and cleavage of poly (ADP?ribose) polymerase were induced by ferrichrome treatment, suggesting that ferrichrome induced apoptosis in pancreatic cancer cells. A transcriptome analysis revealed that the expression p53?associated mRNAs was significantly altered by ferrichrome treatment. Thus, the tumor?suppressive effects of probiotics may mediated by probiotic?derived molecules, such as ferrichrome, which may have applications as an antitumor drug, even in refractory and 5?FU?resistant pancreatic cancer.

SUBMITTER: Kita A 

PROVIDER: S-EPMC7384844 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature